🔗 Share this article

Given that the United States continues making historic changes to its vaccine recommendations, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by questioning COVID-19 shots throughout the pandemic and has focused upon alleged fatalities after Covid immunization in her recent time at the FDA.

Planned Overhauls to Childhood Vaccine Schedule

Public health authorities had intended to unveil major changes to the pediatric vaccination calendar in December, aligning the US with Denmark’s vaccine program, sources say – a major change that would put the US at odds with much of the international standard with insufficient data for public health gain. The announcement has been postponed until the next year.

Instead of the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth person to head the center this year.

A New Direction at the Agency

The acting appointment could signify a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad solidify control at the FDA – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Høeg has frequently advocated for halting certain childhood vaccine recommendations in the US so as to align more similar to Denmark, a country with nationalized medicine and a number of inhabitants roughly the size of Wisconsin’s.

To date statements, she has kept her attention on immunizations – traditionally the purview of Prasad, director of the FDA’s vaccine center – instead of pharmaceutical oversight.

Doubts Over Qualifications

The appointee has little discernible background in pharmaceutical research, approval processes or management, which has been customary for past heads of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have the requisite experience” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in running a large organization. She has no expertise in drug approvals.”

Previous directors of the center would “understand legal statutes and the science of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that prior appointees who headed CBER have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock pointed out.

“The public just zeroes in on the novel medication approvals, but the off-patent medication office approves numerous off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and more, and every single one have to be looked after,” Woodcock explained. “The responsibility you neglect, that is the part that I always told people is going to cause problems.”

Additionally, a major management element to the position, which supervises over 5,000 staff members. “It is a huge management job, if you perform it correctly,” Woodcock concluded.

Response and Contentious Programs

When asked about inquiries about Dr. Høeg's qualifications and whether this assignment represents greater collaboration among regulatory chiefs on vaccines, a press secretary said that the “inquiries rely on flawed premises”.

“This background aligns with the responsibilities of her job,” the spokesperson said, pointing to the months Høeg spent counseling the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Høeg inherits the commissioner’s new priority voucher program, a disputed rapid therapy clearance system that allegedly concerned her former heads. “By what process are these therapies being selected for this expedited pathway? Who makes the calls?” Dr. Howard said. “There is a lot of secrecy going on at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards laxer regulations of all drugs, aside from vaccines.”

Public History on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if troubling, track record, critics have noted. She authored a study using unverified volunteer-provided data to estimate the frequency of myocarditis following COVID-19 immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccines are pose a greater threat than they are.

Included in her “desired changes” for the current federal leadership featured revising regulations for novel immunizations and halting “non-essential” immunizations, she remarked following the vote on a audio program. At the agency, Høeg has reportedly suggested barring young men from obtaining Covid vaccines.

“She’s an complete dogmatist who commences with her conclusions and tailors the evidence to retrofit the data in a extremely misleading, fraudulent fashion,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg aligned with other skeptics, {like|